Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to -$5.9 million.

  • Lifecore Biomedical's Change in Accured Expenses fell 159.96% to -$3.5 million in Q2 2025 from the same period last year, while for May 2025 it was -$5.9 million, marking a year-over-year decrease of 458.08%. This contributed to the annual value of -$5.9 million for FY2025, which is 458.08% down from last year.
  • According to the latest figures from FY2025, Lifecore Biomedical's Change in Accured Expenses is -$5.9 million, which was down 458.08% from $1.7 million recorded in FY2024.
  • Lifecore Biomedical's Change in Accured Expenses' 5-year high stood at $3.3 million during FY2021, with a 5-year trough of -$5.9 million in FY2025.
  • In the last 3 years, Lifecore Biomedical's Change in Accured Expenses had a median value of -$4.5 million in 2023 and averaged -$2.9 million.
  • In the last 5 years, Lifecore Biomedical's Change in Accured Expenses skyrocketed by 272.65% in 2021 and then plummeted by 458.08% in 2025.
  • Over the past 5 years, Lifecore Biomedical's Change in Accured Expenses (Yearly) stood at $3.3 million in 2021, then slumped by 177.86% to -$2.5 million in 2022, then crashed by 76.08% to -$4.5 million in 2023, then surged by 136.87% to $1.7 million in 2024, then crashed by 458.08% to -$5.9 million in 2025.